Compare Abbott Laboratories (ABT) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Ryanair Holdings plc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Ryanair Holdings plc trades at $65.42 (market cap $32.49B). The key difference: Abbott Laboratories is far larger — about 5.1× Ryanair Holdings plc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | RYAAY | |
|---|---|---|
Market Cap | $166.94B | $32.49B |
Sector | Health | Industrials |
52-Week High | $136.62 | $73.82 |
52-Week Low | $82.57 | $53.24 |
Enterprise Value | $193.69B | $30.15B |
Dividend Yield | 2.63% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Ryanair Holdings (RYAAY) trades at $66.35, up 1.31% with bullish technical signals from moving averages. The company demonstrates strong fundamentals with a P/E of 14.42, net income margin of 13.98%, and consistent earnings beats. Recent traffic growth of 7% in June 2026 and improved family seating policy reflect operational strength. Cash flow from operations remains robust at $3.42B despite negative net cash flow of -$12M in 2025.
RYAAY presents a compelling investment case with analyst consensus favoring Buy (62.5%) and bullish technical indicators. The airline's debt-free balance sheet, 80% fuel hedge for 2027, and cost leadership provide competitive advantages. Key risks include rising operating costs, macroeconomic uncertainty, and potential regulatory pressures. The stock's current valuation appears reasonable given strong profitability metrics and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
